0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

New lipid-lowering drug now on the market

JAMA. 1982;247(11):1540. doi:10.1001/jama.1982.03320360008004.
Text Size: A A A
Published online

ABSTRACT

A new lipid-lowering agent is now on the market after 11 years of development.

The agent is gemfibrozil (Lopid, 5-[2,5-dimethylphenoxy]-2,2-dimethylpentanoic acid), and it has been the subject of 41 clinical studies in 12 countries. In ten of those studies involving 785 patients, says the manufacturer (Parke-Davis division of Warner-Lambert Company), "triglyceride levels in 80% of the group decreased 35% or to normal, and in 50% of the subjects cholesterol dropped 20% or to normal." Another study involving about 4,000 dyslipidemic patients currently is under way in Helsinki to try to determine if gemfibrozil also can cause regression of atheromas. Before-and-after angiography will be carried out among other studies, and results may be available by 1984.

Marketed as a 300-mg capsule for oral administration, gemfibrozil generally will be given only to patients having a clearly defined risk of coronary heart disease owing to severe familiar hypercholesterolemia who have failed to respond

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();